Adding depth to its portfolio, Gilead has entered into a licensing agreement with Kyverna Therapeutics to develop T cell therapies for the treatment of autoimmune diseases. The deal combines Kyverna’s synthetic regulatory T-cells platform and synNotch technology from Kite Pharma to develop product candidates. Concurrently, Gilead also participated in Kyverna’s Series A financing round, which raised US$25 M.